国际过敏与鼻科学共识声明 : 变应性鼻炎

Wise, Sarah K.; Lin, Sandra Y.; Toskala, Elina; Orlandi, Richard R.; Akdiş, Cezmi A.; Alt, Jeremiah A.; Azar, Antoine; Baroody, Fuad M.; Bachert, Claus; Canonica, G. W.; Chacko, Thomas; Cingi, Cemal; Ciprandi, Giorgio; Corey, Jacquelynne P.; Cox, Linda; Creticos, Peter S.; Čustović, Adnan; Damask, Cecelia; DeConde, Adam S.; DelGaudio, John M.; Ebert, Charles S.; Eloy, Jean Anderson; Flanagan, Carrie E.; Fokkens, Wytske J.; Franzese, Christine B.; Gosepath, Jan; Halderman, Ashleigh A.; Hamilton, Robert G.; Hoffman, Hans Jürgen; Hohlfeld, Jens M.; Houser, Steven M.; Hwang, Peter H.; Incorvaia, Cristoforo; Jarvis, Déborah; Khalid, Ayesha N.; Kilpeläinen, Maritta; Kingdom, Todd T.; Krouse, Helene J.; Larenas‐linnemann, Desiree; Laury, Adrienne M.; Lee, Stella E.; Levy, Joshua M.; Luong, Amber U.; Marple, Bradley F.; McCoul, Edward D.; McMains, Kevin C.; Melén, Erik; Mims, James W.; Moscato, Gianna; Mullol, Joaquim; Nelson, Harold S.; Patadia, Monica; Pawankar, Ruby; Pfaar, Oliver; Platt, Michael P.; Reisacher, William R.; Rondón, Carmen; Rudmik, Luke; Ryan, Matthew W.; Sastre, Joaquı́n; Schlosser, Rodney J.; Settipane, Russell A.; Sharma, Hemant; Sheikh, Aziz; Smith, Timothy L.; Tantilipikorn, Pongsakorn; Tversky, Jody; Veling, Maria C.; Wang, De Yun; Westman, Marit; Wickman, Magnus; Zacharek, Mark A.

doi:10.1002/alr.22073_c

Cited by 74 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines and the International Consensus Statement on Allergy and Rhinology suggest allergen-specific immunotherapy (AIT) for patients with moderate to severe allergic rhinoconjunctivitis (ARC) who were not improved by medications (1,2) . Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the standard treatments of AIT (3,4) .…”

Section: Introductionmentioning

confidence: 99%

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Hoang¹,

Seresirikachorn²,

Chitsuthipakorn³

et al. 2021

Rhin

View full text Add to dashboard Cite

BACKGROUND: Intralymphatic immunotherapy (ILIT) is a new route of allergen-specific immunotherapy. Data confirming its effect is restricted to a small number of studies. METHODOLOGY: A systematic review with meta-analysis was conducted. The short-term (less than 24 weeks), medium-term (24-52 weeks), and long-term (more than 52 weeks) effects of ILIT in patients with allergic rhinoconjunctivitis (ARC) were assessed. The outcomes were combined symptom and medication scores (CSMS), symptoms visual analog scale (VAS), disease-specific quality of life (QOL), specific IgG4 level, specific IgE level, and adverse events. RESULTS: Eleven randomized controlled trials and 2 cohorts (483 participants) were included. Compared with placebo, short term benefits of ILIT for seasonal ARC improved CSMS, improved VAS and increased specific IgG4 level but did not change QOL or specific IgE level. Medium-term effect improved VAS. Data on the long-term benefit of ILIT remain unavailable and require longer term follow-up studies. There were no clinical benefits of ILIT for perennial ARC. ILIT was safe and well-tolerated. CONCLUSION: ILIT showed short-term benefits for seasonal ARC. The sustained effects of ILIT were inconclusive. It was well tolerated.

show abstract

Section: Introductionmentioning

confidence: 99%

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Hoang¹,

Seresirikachorn²,

Chitsuthipakorn³

et al. 2021

Rhin

View full text Add to dashboard Cite

show abstract

“…Seidman et al (2) , in a clinical practice guideline, does not recommend the use of INCS+LTRA combination after the failure of INCS in monotherapy for the management AR and it is not recommended either by the International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR) regarding its effectiveness (32) . In practice, INCS in monotherapy or the formulation MP-AzeFlu of INCS should be an initial treatment for patients with moderate to severe persistent AR or nasal obstruction (32,33) . The findings of our meta-analysis do not recom- as or less effective than oral antihistamines for AR (34) ; moreover, it is less effective than INCS2.…”

Section: Discussionmentioning

confidence: 99%

“…The findings of our meta-analysis do not recom- as or less effective than oral antihistamines for AR (34) ; moreover, it is less effective than INCS2. LTRA combined with oral H1 antihistamine might be considered when failure of antihistamine monotherapy (2,32,35) . In this situation, the formulation MP-AzeFlu of INCS is better evidence-based option validated by previous studies (36) , meta-analysis (37,38) , and clinical guidelines (33,39) .…”

Section: Discussionmentioning

confidence: 99%

Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis

Seresirikachorn¹,

Mullol²,

Limitlaohaphan³

et al. 2021

Rhin

View full text Add to dashboard Cite

Background: Intranasal corticosteroids (INCS) and leukotriene receptor antagonist (LTRA) have different mechanisms of action. The combination of INCS and LTRA (INCS+LTRA) are utilized to control the allergic rhinitis (AR) symptoms. The effects of this com- bination have not been made evident yet. Methodology: Randomized controlled trials studying the effects of INCS+LTRA vs INCS in monotherapy on rhinoconjunctivitis symptoms in patients with AR were included. Data were pooled for meta-analysis. The outcomes were nasal symptoms, ocular symptoms, disease-specific quality of life (QOL), and adverse events. Results: Six studies (358 participants) met the inclusion criteria. There were no differences between INCS+LTRA and INCS mono- therapy on composite nasal symptom score, total daytime symptom score, total night time symptom score, disease-specific QOL and adverse events. The results favoured the effects of INCS-LTRA on ocular symptoms. Conclusions: The effects of the INCS+LTRA combination are not different from INCS in monotherapy in the improvement of both nasal symptoms and patient's QOL. The combination may, however, be better on improving ocular symptoms.

show abstract

“…The International Consensus Statement on Allergy and Rhinology and the American Academy of Otolaryngology-Head and Neck Surgery Foundation Clinical Practice Guideline for Allergic Rhinitis both recommend a first-line treatment of intranasal steroid spray and suggest clinicians may offer combination therapy in patients with persistent symptoms. 1,17 The American College of Allergy Asthma and Immunology reported that 52% of allergists and 39% of primary care physicians prescribe more than 1 oral antihistamine, with 75% of those physicians citing inadequate symptom relief as the rationale for prescribing multiple drugs. 18 Because adherence to AR treatment has been reported to be around 50%, and polypharmacy is known to further decrease adherence, combination medications in a single delivery system may be helpful to negate these effects.…”

Section: Discussionmentioning

confidence: 99%

“…A llergic rhinitis (AR) is a condition that may result from allergen exposure causing IgE-mediated inflammation of the nasal mucosa. 1 Symptomatology varies but often includes sneezing, itchy eyes, watery eyes, nasal congestion, clear rhinorrhea, postnasal drip, and/or facial pressure. These symptoms can have further implications for additional comorbidities, including sinusitis and asthma, as well as have a significant impact on a person's quality of life.…”

mentioning

confidence: 99%

Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta‐analysis

Debbaneh

Bareiss

Wise

et al. 2019

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

Objective Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. This systematic review and meta-analysis examines existing literature to determine efficacy in treating allergic rhinitis compared to monotherapy. Data Sources The PubMed, EMBASE, Cochrane, and MEDLINE databases were systematically searched for randomized controlled trials using AzeFlu nasal spray. Review Methods Randomized, controlled trials that reported symptom relief of allergic rhinitis in males and females of all ages were included. Results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard. Results Systematic review identified 8 articles suitable for review. The risk of bias was generally low. All studies exhibited a greater decrease in patient-reported symptom scores in patients treated with combination therapy compared to monotherapy or placebo. Meta-analysis revealed superiority of combination therapy in reducing Total Nasal Symptom Score compared to placebo (mean change from baseline: −2.41; 95% confidence interval [CI], −2.82 to −1.99; P < .001; I 2 = 60%), azelastine (mean change from baseline: −1.40; 95% CI, −1.82 to −0.98; P < .001; I 2 = 0%), and fluticasone (mean change from baseline: −0.74; 95% CI, −1.17 to −0.31; P < .001; I 2 = 12%). Conclusion Current evidence supports both efficacy and superiority of combination intranasal azelastine and fluticasone in reducing patient-reported symptom scores in patients with allergic rhinitis. Combination nasal spray should be considered as second-line therapy in patients with allergic rhinitis that is not controlled with monotherapy.

show abstract

国际过敏与鼻科学共识声明 : 变应性鼻炎

Cited by 74 publications

References 0 publications

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis

Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis

Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta‐analysis

Contact Info

Product

Resources

About